- Home
- MAIA vs ECOR Comparison
MAIA vs ECOR Comparison
Compare MAIA & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- ECOR
- Stock Information
- Founded
- MAIA 2018
- ECOR 2005
- Country
- MAIA United States
- ECOR United States
- Employees
- MAIA N/A
- ECOR N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MAIA Health Care
- ECOR Health Care
- Exchange
- MAIA Nasdaq
- ECOR Nasdaq
- Market Cap
- MAIA 46.7M
- ECOR 40.1M
- IPO Year
- MAIA 2022
- ECOR 2018
- Fundamental
- Price
- MAIA $2.03
- ECOR $4.98
- Analyst Decision
- MAIA
- ECOR Strong Buy
- Analyst Count
- MAIA 0
- ECOR 2
- Target Price
- MAIA N/A
- ECOR $25.50
- AVG Volume (30 Days)
- MAIA 319.8K
- ECOR 122.7K
- Earning Date
- MAIA 05-20-2025
- ECOR 05-07-2025
- Dividend Yield
- MAIA N/A
- ECOR N/A
- EPS Growth
- MAIA N/A
- ECOR N/A
- EPS
- MAIA N/A
- ECOR N/A
- Revenue
- MAIA N/A
- ECOR $25,182,000.00
- Revenue This Year
- MAIA N/A
- ECOR $32.20
- Revenue Next Year
- MAIA N/A
- ECOR $46.27
- P/E Ratio
- MAIA N/A
- ECOR N/A
- Revenue Growth
- MAIA N/A
- ECOR 57.09
- 52 Week Low
- MAIA $1.40
- ECOR $5.02
- 52 Week High
- MAIA $5.99
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- MAIA 53.91
- ECOR 30.12
- Support Level
- MAIA $1.80
- ECOR $6.01
- Resistance Level
- MAIA $2.18
- ECOR $7.14
- Average True Range (ATR)
- MAIA 0.30
- ECOR 0.75
- MACD
- MAIA -0.01
- ECOR -0.03
- Stochastic Oscillator
- MAIA 30.29
- ECOR 4.80
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.